Method of predicting responsiveness of B cell lineage malignancies to active immunotherapy
View Patent ↗Predictive biomarkers identify those patients suffering from immunoglobulin positive (Ig + ) B lineage malignancies that are responsive to active immunotherapy, where the active immunotherapy comprises vaccination with a tumor-specific idiotype-immunogen. It is shown herein that patient responsiveness to the idiotype-immunogen is dependent upon the sequence of the immunogen, where an immunogen having a low number of tyrosine residues in the CDR1 (herein termed CDR1-Y 10 ) regions of one or both of the immunogen heavy and light chains is predictive of a positive anti-tumor response, while a high number of CDR1 tyrosine residues (herein termed CDR1-Y hi ) is predictive of a low anti tumor response.
1. A method for administering a vaccine to a patient suffering from an immunoglobulin positive (Ig+) B lineage malignancy, the method comprising:
obtaining a biological sample from a patient suspected of having an Ig+B lineage malignancy, which biological sample comprises tumor cells;
detecting three of fewer tyrosine residues in one or both of the Ig heavy and Ig light chain CDR1 regions in the biological sample; and
administering a vaccine comprising said tumor specific idiotype to the patient.
2. The method of claim 1 wherein the biological sample is selected from biopsy of an enlarged lymph node (LN) or other extranodal tissue involved by lymphoma; fine needle aspiration of an enlarged LN; blood; and bone marrow aspiration.
3. The method of claim 1 , wherein the immunoglobulin positive (Ig+) B lineage malignancy is a non-Hodgkin lymphoma (NHL).
4. The method of claim 3 , wherein the NHL is a follicular lymphoma.